Literature DB >> 21165772

Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice.

Reginald M Gorczynski1, David A Clark, Nuray Erin, Ismat Khatri.   

Abstract

Previous studies have confirmed that levels of CD200 expression on the cells of the transplantable EMT6 mouse breast cancer line are increased markedly during growth in immunocompetent mice, unlike the persistent low levels of expression observed in NOD-SCID.IL-2(γr-/-) mice or mice with generalized over-expression of a CD200 transgene (CD200(tg) mice). Faster tumor growth occurs in both of these latter mice, with decreased evidence for a host immune reaction in lymph nodes draining the tumor (DLN). We now report evidence for a role for CD200 expression (by the host and/or tumor cells) in increased seeding of tumor cells to DLN in immunocompromised (CD200(tg) or NOD-SCID.IL-2(γr-/-)) vs immunocompetent mice, by limiting dilution cloning of tumor cells from DLN (vs contralateral lymph nodes, CLN), using control and GFP-tagged EMT6 cells. Neutralization of expressed CD200 by anti-CD200mAbs decreased the tumor metastasis at the same time as increasing detection of cytotoxic anti-tumor immune cells in DLN. Infusion of either anti-CD4 to deplete T-effector cells, or anti-TGFβ antibody, increased metastasis to DLN, as did indeed the infusion of EMT6 cells selected for the loss of TGFβRII expression. It is concluded that the increased CD200 expression by breast cancer cells (and/or host tissue) may be an important variable involved in determining the risk of metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21165772     DOI: 10.1007/s10549-010-1259-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

1.  Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response.

Authors:  N Erin; A Podnos; G Tanriover; Ö Duymuş; E Cote; I Khatri; R M Gorczynski
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

2.  Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.

Authors:  Zhengming Xiong; Elisabet Ampudia-Mesias; Rob Shaver; Craig M Horbinski; Christopher L Moertel; Michael R Olin
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

Review 3.  CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.

Authors:  Jin-Qing Liu; Aiyan Hu; Jianmin Zhu; Jianyu Yu; Fatemeh Talebian; Xue-Feng Bai
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma.

Authors:  Jin-Qing Liu; Fatemeh Talebian; Lisha Wu; Zhihao Liu; Ming-Song Li; Laichu Wu; Jianmin Zhu; Joseph Markowitz; William E Carson; Sujit Basu; Xue-Feng Bai
Journal:  J Immunol       Date:  2016-07-06       Impact factor: 5.422

5.  CXCL8, IL-1β and sCD200 are pro-inflammatory cytokines and their levels increase in the circulation of breast carcinoma patients.

Authors:  Betul Celik; Arzu Didem Yalcin; Gizem Esra Genc; Tangul Bulut; Sibel Kuloglu Genc; Saadet Gumuslu
Journal:  Biomed Rep       Date:  2016-06-30

Review 6.  Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.

Authors:  Mahmoud S Alghamri; Brandon L McClellan; Carson S Hartlage; Santiago Haase; Syed Mohd Faisal; Rohit Thalla; Ali Dabaja; Kaushik Banerjee; Stephen V Carney; Anzar A Mujeeb; Michael R Olin; James J Moon; Anna Schwendeman; Pedro R Lowenstein; Maria G Castro
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.988

7.  CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.

Authors:  Elisabet Ampudia-Mesias; Francisco Puerta-Martinez; Miurel Bridges; David Zellmer; Andrew Janeiro; Matt Strokes; Yuk Y Sham; Ayman Taher; Maria G Castro; Christopher L Moertel; G Elizabeth Pluhar; Michael R Olin
Journal:  Neurotherapeutics       Date:  2021-04-07       Impact factor: 6.088

8.  Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.

Authors:  Reginald M Gorczynski; Zhiqi Chen; Nuray Erin; Ismat Khatri; Anna Podnos
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

9.  Gene network analysis to determine the effect of hypoxia-associated genes on brain damages and tumorigenesis using an avian model.

Authors:  Hamed Kharrati-Koopaee; Esmaeil Ebrahimie; Mohammad Dadpasand; Ali Niazi; Rugang Tian; Ali Esmailizadeh
Journal:  J Genet Eng Biotechnol       Date:  2021-07-08

10.  Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.

Authors:  Reginald M Gorczynski; Zhiqi Chen; Ismat Khatri; Anna Podnos; Kai Yu
Journal:  Breast Cancer Res Treat       Date:  2013-10-29       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.